| Description | RS 0481 modulates the immune response and rebuilds lymphocyte populations damaged by tumor growth in animals. |
| In vivo | 在小鼠模型中，RS-0481的给药剂量范围测试了0.1、1和10 mg/kg，这些剂量都是通过口服途径给予X5563肿瘤负担小鼠。给药计划包括在肿瘤接种后第1-5天或第12-16天连续5天进行。研究发现，这些剂量都能显著增强抗肿瘤免疫反应，包括肿瘤特异性细胞毒性T淋巴细胞（CTL）、迟发型超敏反应T细胞（TDTH）以及非特异性淋巴因子激活杀伤细胞样细胞的反应。同时，RS-0481还能增强肿瘤负担小鼠巨噬细胞的肿瘤抑制作用，但对正常小鼠的巨噬细胞没有影响。[1] |
| Synonyms | RS-0481, RS0481 |
| molecular weight | 340.44 |
| Molecular formula | C19H20N2O2S |
| CAS | 126769-16-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Kurakata S, et al.Modulation of the immune response to tumors by a novel synthetic compound, (4R)-3-benzoyl-N-[(1R)-1-phenylethyl]-4-thiazolidinecarboxamide (RS-0481). Cancer Immunol Immunother. 1991;33(2):71-9. |